DCM
ADPT icon

Dupont Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Dupont Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,650
Closed -$112K – 754
2022
Q4 		$112K Sell
14,650
-1,571
-10% -$12.2K 0.01% 917
2022
Q3 		$115K Buy
+16,221
New +$153K 0.01% 989

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Dupont Capital Management's ADPT Position: Q1 2023 in Review

Dupont Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2023, closing a stake of 14,650 shares — an estimated $112K sold.

Dupont Capital Management first reported a position in ADPT in Q3 2022 and held it in 2 quarters. The position peaked at $115K in Q3 2022. 226 funds tracked by Wall St. Rank hold ADPT as of Q1 2023.

  • Dupont Capital Management reported no remaining Adaptive Biotechnologies position as of Q1 2023 after selling out during the quarter.
  • Dupont Capital Management sold 14,650 Adaptive Biotechnologies shares in Q1 2023, an estimated $112K.
  • Dupont Capital Management first reported a position in Adaptive Biotechnologies in Q3 2022 and held it in 2 quarters.
  • Dupont Capital Management's Adaptive Biotechnologies position peaked at $115K in Q3 2022.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.